The impact of coronavirus disease 2019 on acute coronary syndrome: Differences between epidemic waves

Vincenzo Sucato1, Giusy Sausa1, Grazia Gambino1

  • 1Division of Cardiology, University Hospital Paolo Giaccone, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Italy.

Insights

The COVID-19 pandemic significantly impacted acute coronary syndrome (ACS) patient care, with the first wave showing the greatest management challenges due to hospital unpreparedness and patient fear. Subsequent waves saw increased hospitalizations and changes in treatment times and outcomes.

Area of Science:

  • Cardiology
  • Public Health
  • Epidemiology

Background:

  • The COVID-19 pandemic has had indirect effects on cardiovascular health systems, particularly for patients with Acute Coronary Syndrome (ACS).
  • Limited attention has been given to the pandemic's impact on ACS management across different epidemic waves.
  • Understanding these impacts is crucial for optimizing cardiovascular care during health crises.

Purpose of the Study:

  • To compare epidemiological, clinical, and management differences in patients hospitalized for ACS across four COVID-19 epidemic waves.
  • To highlight the burden of the pandemic on the management of Acute Coronary Syndrome.
  • To analyze changes in ACS patient outcomes and healthcare delivery during the pandemic.

Main Methods:

  • A retrospective observational study of 98 patients admitted to a Coronary Intensive Care Unit (CICU) for ACS between March 2020 and March 2022.
  • Patients were divided into four groups, each representing a distinct COVID-19 epidemic wave.
  • Data on hospitalization rates, treatment times (door-to-balloon), length of stay, and mortality were analyzed.

Main Results:

  • Hospitalizations for ACS increased progressively, with a 178% rise in the third wave compared to the first (p=0.003).
  • Non-ST-Elevation Myocardial Infarction (NSTEMI) hospitalizations increased by 900% in the third wave.
  • Longer door-to-balloon times were observed in the third wave; average hospital stay and mortality varied across waves, with the highest mortality in the fourth wave (9.5%).

Conclusions:

  • The management of ACS was most severely affected during the initial pandemic wave due to hospital unpreparedness and patient reluctance to seek care.
  • Fear of infection and system unpreparedness significantly hampered ACS care delivery.
  • Pandemic waves influenced ACS hospitalization rates, treatment delays, and patient mortality, necessitating adaptive strategies in cardiovascular care.
Abstract

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Coronary Circulation01:21

Coronary Circulation

The heart, an organ critical to survival, gets nourishment not from the blood it pumps but from a separate circulation system known as coronary circulation. This is the shortest circulation in the body and is responsible for supplying the heart with the nutrients it needs to function effectively.
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
2.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
481
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
126
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
184
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
192